AB 1926: Health care coverage: regional enteritis.
- Session Year: 2023-2024
- House: Assembly
- Latest Version Date: 2024-03-19
Current Status:
Failed
(2024-08-15: In committee: Held under submission.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of disability insurers, including health insurers, by the Department of Insurance. Existing law requires a health care service plan contract and disability insurance policy that provides coverage for hospital, medical, or surgical expenses and is issued, amended, delivered, or renewed on and after July 1, 2000, to provide coverage for the testing and treatment of phenylketonuria, including coverage for the formulas and special food products that are part of a prescribed diet, as specified.
This bill would require a health care service plan contract or disability insurance policy that provides coverage for hospital, medical, or surgical expenses and is issued, amended, delivered, or renewed on and after July 1, 2025, to provide coverage for dietary enteral formulas, as defined, for the treatment of other chronic digestive diseases and inherited metabolic disorders, regional enteritis, as specified. The bill would specify that these provisions do not apply to Medi-Cal managed care plans to the extent that the services are excluded from coverage under the contract between the Medi-Cal managed care plan and the State Department of Health Care Services. Because a violation of the bills requirements by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of disability insurers, including health insurers, by the Department of Insurance. Existing law requires a health care service plan contract and disability insurance policy that provides coverage for hospital, medical, or surgical expenses and is issued, amended, delivered, or renewed on and after July 1, 2000, to provide coverage for the testing and treatment of phenylketonuria, including coverage for the formulas and special food products that are part of a prescribed diet, as specified.
This bill would require a health care service plan contract or disability insurance policy that provides coverage for hospital, medical, or surgical expenses and is issued, amended, delivered, or renewed on and after July 1, 2025, to provide coverage for formulas, as defined, for the treatment of other chronic digestive diseases and inherited metabolic disorders, as specified. The bill would specify that these provisions do not apply to Medi-Cal managed care plans to the extent that the services are excluded from coverage under the contract between the Medi-Cal managed care plan and the State Department of Health Care Services. Because a violation of the bills requirements by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(a)(1)On and after July 1, 2025, every health care service plan contract, except a specialized health care service plan contract, issued, amended, delivered, or renewed in this state that provides coverage for hospital, medical, or surgical expenses shall provide coverage for dietary enteral formulas, as defined in subdivision (c), for the treatment of chronic digestive diseases, including, but not limited to, Crohns disease, and inherited metabolic disorders. regional enteritis.
(2)Coverage for the treatment of the chronic digestive diseases described in paragraph (1) shall include those formulas that are part of a diet dietary enteral formulas prescribed by a licensed physician and managed by a health care professional in consultation with a physician who specializes in the treatment of chronic digestive diseases and inherited metabolic disorders and who participates in or is authorized by the health plan, provided that the diet dietary enteral formula is deemed medically necessary to avert the development of serious physical or mental disabilities or to promote normal development or function as a consequence of chronic digestive diseases and inherited metabolic disorders. regional enteritis.
(b)This section does not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000) or Chapter 8 (commencing with Section 14200) of Part 3 of Division 9 of the Welfare and Institutions Code, to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plan and the State Department of Health Care Services.
(c)For purposes of this section, formula dietary enteral formula means an enteral product or enteral products, including nutritional drinks, for use formula or enteral formulas that may be taken orally at home that are prescribed by a physician or nurse practitioner, or ordered by a registered dietician upon referral by a health care provider authorized to prescribe dietary treatments, as medically necessary for the treatment of chronic digestive diseases and inherited metabolic disorders. regional enteritis.
SEC. 2.Section 10123.895 is added to the Insurance Code, to read:10123.895.(a)(1)On and after July 1, 2025, every policy of disability insurance, except a specialized disability insurance policy that provides coverage only for dental or vision benefits, issued, amended, delivered, or renewed in this state that provides coverage for hospital, medical, or surgical expenses shall provide coverage for dietary enteral formulas, as defined in subdivision (c), for the treatment of chronic digestive diseases, including, but not limited to, Crohns disease, and inherited metabolic disorders. regional enteritis.
(2)Coverage for the treatment of the chronic digestive diseases described in paragraph (1) shall include those formulas that are part of a diet dietary enteral formulas prescribed by a licensed physician and managed by a health care professional in consultation with a physician who specializes in the treatment of chronic digestive diseases and inherited metabolic disorders and who participates in or is authorized by the disability insurer, provided that the diet dietary enteral formula is deemed medically necessary to avert the development of serious physical or mental disabilities or to promote normal development or function as a consequence of chronic digestive diseases and inherited metabolic disorders. regional enteritis.
(b)This section does not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000) or Chapter 8 (commencing with Section 14200) of Part 3 of Division 9 of the Welfare and Institutions Code, to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plan and the State Department of Health Care Services.
(c)For purposes of this section, formula dietary enteral formula means an enteral product or enteral products, including nutritional drinks, for use formula or enteral formulas that may be taken orally at home that are prescribed by a physician or nurse practitioner, or ordered by a registered dietician upon referral by a health care provider authorized to prescribe dietary treatments, as medically necessary for the treatment of chronic digestive diseases and inherited metabolic disorders. regional enteritis.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)(1)On and after July 1, 2025, every health care service plan contract, except a specialized health care service plan contract, issued, amended, delivered, or renewed in this state that provides coverage for hospital, medical, or surgical expenses shall provide coverage for formulas, as defined in subdivision (c), for the treatment of chronic digestive diseases, including, but not limited to, Crohns disease, and inherited metabolic disorders.
(2)Coverage for the treatment of the chronic digestive diseases described in paragraph (1) shall include those formulas that are part of a diet prescribed by a licensed physician and managed by a health care professional in consultation with a physician who specializes in the treatment of chronic digestive diseases and inherited metabolic disorders and who participates in or is authorized by the health plan, provided that the diet is deemed medically necessary to avert the development of serious physical or mental disabilities or to promote normal development or function as a consequence of chronic digestive diseases and inherited metabolic disorders.
(b)This section does not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000) or Chapter 8 (commencing with Section 14200) of Part 3 of Division 9 of the Welfare and Institutions Code, to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plan and the State Department of Health Care Services.
(c)For purposes of this section, formula means an enteral product or enteral products, including nutritional drinks, for use at home that are prescribed by a physician or nurse practitioner, or ordered by a registered dietician upon referral by a health care provider authorized to prescribe dietary treatments, as medically necessary for the treatment of chronic digestive diseases and inherited metabolic disorders.
SEC. 2.Section 10123.895 is added to the Insurance Code, to read:10123.895.(a)(1)On and after July 1, 2025, every policy of disability insurance, except a specialized disability insurance policy that provides coverage only for dental or vision benefits, issued, amended, delivered, or renewed in this state that provides coverage for hospital, medical, or surgical expenses shall provide coverage for formulas, as defined in subdivision (c), for the treatment of chronic digestive diseases, including, but not limited to, Crohns disease, and inherited metabolic disorders.
(2)Coverage for the treatment of the chronic digestive diseases described in paragraph (1) shall include those formulas that are part of a diet prescribed by a licensed physician and managed by a health care professional in consultation with a physician who specializes in the treatment of chronic digestive diseases and inherited metabolic disorders and who participates in or is authorized by the disability insurer, provided that the diet is deemed medically necessary to avert the development of serious physical or mental disabilities or to promote normal development or function as a consequence of chronic digestive diseases and inherited metabolic disorders.
(b)This section does not apply to Medi-Cal managed care plans contracting with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000) or Chapter 8 (commencing with Section 14200) of Part 3 of Division 9 of the Welfare and Institutions Code, to the extent that the services described in this section are excluded from coverage under the contract between the Medi-Cal managed care plan and the State Department of Health Care Services.
(c)For purposes of this section, formula means an enteral product or enteral products, including nutritional drinks, for use at home that are prescribed by a physician or nurse practitioner, or ordered by a registered dietician upon referral by a health care provider authorized to prescribe dietary treatments, as medically necessary for the treatment of chronic digestive diseases and inherited metabolic disorders.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| Aug 15, 2024 | In committee: Held under submission. |
| Jun 24, 2024 | In committee: Referred to suspense file. |
| Jun 13, 2024 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 8. Noes 0.) (June 12). Re-referred to Com. on APPR. |
| May 29, 2024 | Referred to Com. on HEALTH. |
| May 22, 2024 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 21, 2024 | Read third time. Passed. Ordered to the Senate. (Ayes 67. Noes 0. Page 5404.) |
| May 20, 2024 | Read second time. Ordered to third reading. |
| May 16, 2024 | From committee: Do pass. (Ayes 14. Noes 1.) (May 16). |
| Apr 17, 2024 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| Apr 3, 2024 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 15. Noes 0.) (April 2). Re-referred to Com. on APPR. |
| Mar 20, 2024 | Re-referred to Com. on HEALTH. |
| Mar 19, 2024 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Mar 15, 2024 | In committee: Set, first hearing. Hearing canceled at the request of author. |
| Feb 5, 2024 | Referred to Com. on HEALTH. |
| Jan 26, 2024 | From printer. May be heard in committee February 25. |
| Jan 25, 2024 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Jun 24, 2024 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jun 12, 2024 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| May 21, 2024 | AB 1926 Connolly Assembly Third Reading | Assembly Floor |
Passed |
|
| May 16, 2024 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 2, 2024 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| AmericaS Health Insurance Plans | ** Against | |
| Association Of California Life And Health Insurance Companies | ** Against | |
| California Association Of Health Plans | ** Against | |
| California Association Of Medical Product Suppliers | ** Support | |
| California Children's Hospital Assn | ** Support | |
| Children'S Specialty Care Coalition | ** Support | |
| Crohn’s & Colitis Foundation | ** Support |
SENATE COMMITTEE ON
Senator Anna Caballero, Chair
2023 - 2024 Regular Session
AB 1926 (Connolly) - Health care coverage: regional enteritis
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
AB 1926 would require health plan contracts and insurance policies to provide coverage for dietary enteral formulas for the treatment of regional enteritis (Crohn’s disease).
Fiscal Impact:
- The Department of Managed Health Care (DMHC) estimates costs to be approximately $35,000 in 2024-25, $489,000 in 2025-26, $557,000 in 2026-27, $558,000 in 2027-28, $559,000 in 2028-29, and $560,000 in 2029-30 and annually thereafter for state administration (Managed Care Fund).
- The California Department of Insurance (CDI) estimates one-time costs of $3,000 for state administration (Insurance Fund).
- The California Public Employees' Retirement System (CalPERS) does not anticipate a significant fiscal impact.
Background:
The DMHC regulates health plans under the Knox-Keene Act and the CDI regulates health insurance. Current law requires health plans and disability insurance policies that provide coverage for hospital, medical, or surgical expenses to provide coverage for the testing and treatment of phenylketonuria (PKU) under the terms and conditions of the plan contract or policy. PKU is one type of an inherited metabolic disorder, which is a genetic disorder that affects an individual's ability to metabolize nutrients due to an enzymatic or transporter deficiency.
Health coverage for treatment of PKU includes coverage of formulas and special food products that are part of a diet prescribed by a licensed physician and managed by a health care professional in consultation with a physician who specializes in the treatment of metabolic disease and who participates in or is authorized by the plan or insurer, provided the diet is deemed medically necessary to avert the development of serious physical or mental disabilities or to promote normal development or function as a consequence of PKU. Current law requires this coverage to the extent the cost exceeds the cost of a normal diet.
According to the National Cancer Institute, regional enteritis is a condition in which the gastrointestinal tract is inflamed over a long period of time and usually affects the small intestine and colon. Symptoms include fever, diarrhea, stomach cramps, vomiting, and weight loss. Regional enteritis is a type of inflammatory bowel disease, also called Crohn’s disease. Enteral nutrition can be administered by mouth or feeding tube and is a nutritional therapy for Crohn’s disease patients to help a person meet their daily caloric intake.
Proposed Law:
Specific provisions of the bill would:
- Require health plans and health insurers to provide coverage for “dietary enteral formulas” for the treatment of regional enteritis, as specified.
- Define “dietary enteral formula” as enteral formula or enteral formulas that may be taken orally at home that are prescribed by a physician or nurse practitioner, or ordered by a registered dietician upon referral by a health care provider authorized to prescribe dietary treatments, as medically necessary for the treatment of regional enteritis.
- Exclude Medi-Cal managed care plans.
Related Legislation:
AB 620 (Connolly, 2023) would have required health plans and health insurers to provide coverage for formulas for the treatment of chronic digestive diseases, including, but not limited to, Crohn’s disease, and inherited metabolic disorders. The bill was vetoed by the Governor.
While current law only requires health plans and insurers to provide coverage for specified treatment for PKU, AB 620 would have additionally required coverage for formulas for the treatment of digestive disorders and other inherited metabolic disorders. AB 1926 would only expand coverage to formulas for the treatment of Crohn’s disease.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Richard Roth, Chair
BILL NO: AB 1926
AUTHOR: | Connolly | ||
VERSION: | March 19, 2024 | ||
HEARING DATE: | June 12, 2024 | ||
CONSULTANT: | Teri Boughton | ||
SUBJECT: Health care coverage: regional enteritis
SUMMARY:
Requires health plan contracts and insurance policies to provide coverage for dietary enteral formulas for the treatment of regional enteritis (Crohn’s Disease).
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act); California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
- Establishes, as California's essential health benefits benchmark, the Kaiser Small Group Health Maintenance Organization, existing California mandates, and ten federal Patient Protection and Affordable Care Act mandated benefits. [HSC §1367.005 and INS §10112.27]
- Requires health plans and disability insurance that provides coverage for hospital, medical, or surgical expenses to provide coverage for the testing and treatment of phenylketonuria (PKU) under the terms and conditions of the plan contract or policy. This includes coverage of formulas and special food products that are part of a diet prescribed by a licensed physician and managed by a health care professional in consultation with a physician who specializes in the treatment of metabolic disease and who participates in or is authorized by the plan or insurer, provided the diet is deemed medically necessary to avert the development of serious physical or mental disabilities or to promote normal development or function as a consequence of PKU. Requires this coverage to the extent the cost exceeds the cost of a normal diet. [HSC §1374.56 and INS §10123.89]
This bill:
- Requires, after July 1, 2025, every health plan contract, or policy of disability insurance, that provides coverage for hospital, medical, or surgical expenses, except a specialized health plan contract and a specialized disability insurance policy that provides coverage for dental or vision benefits, to provide coverage for “dietary enteral formulas” for the treatment of regional enteritis.
- Defines “dietary enteral formula” as an enteral formula or enteral formulas that may be taken orally at home that are prescribed by a physician or nurse practitioner, or ordered by a registered dietician upon referral by a health care provider authorized to prescribe dietary treatments, as medically necessary for the treatment of regional enteritis.
- Requires coverage for the treatment of regional enteritis to include dietary enteral formulas prescribed by a licensed physician and managed by a health care professional in consultation with a physician who specializes in the treatment of chronic digestive diseases and inherited metabolic disorders and who participates in or is authorized by the health plan or disability insurer, provided that the dietary enteral formula is deemed medically necessary to avert the development of serious physical or mental disabilities or to promote normal development or function as a consequence of regional enteritis.
- Excludes Medi-Cal managed care plans to the extent that the services are excluded from coverage under the contract between the Medi-Cal managed care plan and DHCS.
FISCAL EFFECT:
According to the Assembly Appropriations Committee:
- DMHC estimates the total cost of this bill to be approximately $35,000 in fiscal year (FY) 2023-24, $458,000 in FY 2024-25, and $535,000 in FY 2025-26 and annually thereafter (Managed Care Fund). The majority of costs would be incurred by the Help Center, which anticipates additional workload for independent medical review, review organization, and medical expert review contracts. DMHC would also need to develop methodology and conduct health plan reviews for compliance with the requirements of this bill.
- One-time costs to CDI of $3,000 in FY 2024-25 (Insurance Fund).
- Cost pressure of an unknown amount, possibly in the hundreds of thousands of dollars annually, to CalPERS (General Fund, other funds). CHBRP estimated AB 620 (Connolly), of the current legislative session – a broader, but similar, bill – would increase total premiums for CalPERS health plans and insurance policies by $1.4 million; roughly 60% of these premiums are for state enrollees, and an unknown percentage is paid for by the state. Costs associated with this bill would probably be substantially lower.
- According to the Legislative Analyst's Office, the General Fund faces a structural deficit in the tens of billions of dollars over the next several fiscal years.
PRIOR VOTES:
Assembly Floor: | 67 - 0 |
Assembly Appropriations Committee: | 14 - 1 |
Assembly Health Committee: | 15 - 0 |
COMMENTS:
- Author’s statement. According to the author, early treatment options for metabolic and digestive diseases, like Crohn's, have proven to reduce harm and increase quality of life. There is no reason why Californians suffering from chronic illnesses cannot lead full and productive lives. This bill provides patients with a proven successful alternative to certain medications, which healthcare providers may recommend when complications such as weight loss, surgery, obstruction, or severe inflammation, prevent patients from getting the right nutrients.
- Regional enteritis. According to the National Cancer Institute, regional enteritis is a condition in which the gastrointestinal tract is inflamed over a long period of time. It usually affects the small intestine and colon. Symptoms include fever, diarrhea, stomach cramps, vomiting, and weight loss. Regional enteritis increases risk of colorectal cancer and small intestine cancer. It is a type of inflammatory bowel disease (IBD) and is also called Crohn’s disease. Enteral nutrition (EN) can be administered by mouth or feeding tube and is a nutritional therapy for Crohn’s disease patients to help a person meet their daily caloric intake. Elemental EN (EEN) includes amino acids, fats, sugars, vitamins, and minerals. EN can be elemental or non-elemental. Non-elemental are best for people who can digest and absorb nutrients without difficulty. (Akobeng, et.al. 2018)
- CHBRP analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed AB 620 (Connolly of 2023) which is broader, but similar to this bill. Key findings include:
- Assumptions. CHBRP’s analysis focuses primarily on formula and special food products that are administered orally, as those administered via tube feeding are already covered. CHBRP considers the following to be the most common digestive diseases that may benefit from formula and special food products: IBD including Crohn’s disease and ulcerative colitis; cystic fibrosis; eosinophilic enteritis; enteropathy; chronic pancreatitis; and, intestinal malabsorption. This bill is limited to enteral formula for Crohn’s disease. Inherited metabolic disorders are individually rare and estimated to be about 1/3,000 individuals overall. Many of these are diagnosed through newborn screening, which is performed in order to initiate life- and brain-saving treatment early, before irreversible damage or death has occurred. These are often grouped into categories including: disorders of amino acid and protein metabolism (e.g., PKU, for which coverage of formula and special food products is already mandated), disorders of carbohydrate metabolism, and disorders of fatty acid oxidation metabolism. CHBRP assumes that
AB 620 is focused on chronic conditions that may benefit from formula and special food products and would exclude various acute digestive disorders.
- Coverage impacts and enrollees covered. Carriers have some coverage for formulas and special food products consumed orally for inherited metabolic disorders or digestive disorders; however, there are exceptions and limitations to when they are covered. Postmandate, all users have coverage for oral formulas and special food products for inherited metabolic and digestive disorders.
- Medical effectiveness. CHBRP found limited evidence from two Cochrane reviews that nutritional treatment is effective on induction and maintenance of remission in Crohn’s disease and comparatively effective to standard treatment (i.e., drug therapy). CHBRP found insufficient evidence from one systematic review on the efficacy of nutritional treatment for ulcerative colitis. Though the studies in the systematic review provide some evidence regarding the efficacy of nutritional treatment for ulcerative colitis, they were not specific to nutritional treatment alone, but to patients on an EN diet and steroid therapy. CHBRP found insufficient evidence on the efficacy of nutritional treatment for inherited metabolic disorders. No studies were found that examined the effectiveness of nutritional treatment for inherited metabolic disorders, and available evidence on treatment for these disorders are treatment guidelines based on expert opinion. Limiting factors that contribute to this evidence grade are the small number of individuals with these conditions, need for timely treatment, and ethical barriers to conducting other types of studies with this population.
- Utilization and expenditures. Under AB 620, CHBRP anticipated a total of 4,769 enrollees would have new benefit coverage for these products, including 1,507 enrollees using these products at baseline and an additional 3,262 enrollees who begin using these products due to the coverage expansion. In 2024, AB 620 would increase total net annual expenditures by $24,187,000 or 0.02% for enrollees with DMHC-regulated plans and CDI-regulated policies. This is primarily due to a $26,928,000 increase in total health insurance premiums paid by employers and enrollees for newly covered benefits, adjusted by a $2,741,000 decrease in enrollee expenses for covered and/or noncovered benefits. This bill is expected to have less utilization and a lower impact on expenditures than what was identified by CHBRP for AB 620.
- Public health. Due to the limited number of enrollees impacted, CHBRP concluded that passage of AB 620 would have no measurable short-term or long-term public health impact. Although nutritional treatment for inherited metabolic disorders is supported by clinical guidelines, the change in utilization is small, and such disorders are rare. Although utilization of nutritional treatment for digestive disorders would increase, there is:
- Limited evidence that this treatment is effective for inducing or maintaining remission compared to standard drug treatment for Crohn’s disease; and,
- Insufficient evidence on the effect on nutritional treatment for ulcerative colitis.
- Essential health benefits (EHB). CHBRP indicated that AB 620 would not exceed the definition of EHB in California because formula and special food products are considered durable medical equipment and would be encompassed within the “rehabilitative and habilitative services and devices” EHB benefit category. However, the Governor’s veto message for AB 620 suggests that AB 620 may have exceeded California’s EHB, which would require California to defray costs associated with the new mandated benefit. In reviewing California’s EHB benchmark evidence of coverage as reported to the Centers for Medicare and Medicaid Services, elemental dietary enteral formula, when used as a primary therapy for regional enteritis, appears to be covered and not subject to the drug deductible.
- Medi-Cal. According to CHBRP, the Medi-Cal RX provider manual indicates that treatment for PKU or other digestive and inherited metabolic disorders, including formulas and special food products that are prescribed diet, are covered benefits in Medi-Cal.
- Coverage impacts and enrollees covered. Carriers have some coverage for formulas and special food products consumed orally for inherited metabolic disorders or digestive disorders; however, there are exceptions and limitations to when they are covered. Postmandate, all users have coverage for oral formulas and special food products for inherited metabolic and digestive disorders.
- Related legislation. AB 3059 (Weber) requires health plans and insures to cover human milk and human milk derivatives covered under the Medi-Cal program as of 1988. AB 3059 is set to be heard in the Senate Health Committee on June 26, 2024.
SB 1290 (Roth)/AB 2914 (Bonta) express the intent of the Legislature to review California’s EHB benchmark plan and establish a new benchmark plan for the 2027 plan year.
SB 1290/AB 2914 limit the applicability of the current benchmark plan benefits to plan years on or before the 2027 plan year. SB 1290 is pending in the Assembly Health Committee and AB 2914 is pending in the Senate Health Committee.
- Prior legislation. AB 620 (Connolly of 2023) would have required health plans and insurers to cover formulas that are part of a medically necessary diet to avert the development of serious physical or mental disabilities or to promote normal development or function as a consequence of chronic digestive diseases and inherited metabolic disorders. AB 620 was vetoed by Governor Newsom, who stated:
While I support individuals with these conditions having access to the nutritional support they may need, I am concerned this bill would exceed the state's set of essential health benefits, which are established by the state's benchmark plan under the provisions of the federal Affordable Care Act (ACA). As such, this bill's mandate would require the state to defray the costs of coverage in Covered California. This would not only increase ongoing state General Fund costs, but it would set a new precedent by adding requirements that exceed the benchmark plan. A pattern of new coverage mandate bills like this could open the state to millions to billions of dollars in new costs to cover services relating to other health conditions. This creates uncertainty for our healthcare system's affordability.
AB 163 (Emerson of 2009) would have required health plans and health insurers to provide coverage for amino acid-based elemental formulas for the diagnosis and treatment of eosinophilic disorders. AB 163 was held on the Assembly Appropriations Committee Suspense File.
AB 30 (Evans of 2007) would have required health plans and insurers to cover the testing and treatment of inborn errors of metabolism. AB 30 was vetoed by Governor Schwarzenegger who stated:
The addition of a new mandate, no matter how small, will only serve to increase the overall cost of health care. California currently has 44 mandates on its health care service plans and health insurance policies. While these mandates are well-intentioned, the costs associated with guaranteed coverage for a specific condition or treatment means that these costs are passed through to the purchaser and consumer. These mandates are a significant driver of cost. Every day, a growing number of employers and individuals are struggling to pay for their health care. We cannot afford to increase these costs without enacting other measures that improve efforts aimed at prevention, address affordability of care and share responsibility between individuals, providers, employers and government.
SB 148 (Alpert, Chapter 541 of 1999) requires health insurers to cover food supplements prescribed by physicians for the treatment of PKU.
- Support. The Crohn’s and Colitis Foundation, the sponsor of this bill, write despite significant advances in medical care, complications are common, and ultimately occur in about 70% of Crohn’s Disease patients. EN is an important part of managing Crohn’s disease in particular, as it reduces the inflammatory process of the gut, leading to bowel rest and improving postoperative prognosis for those who require surgery. EN is a liquid dietary regimen, which is administered orally, as a drink, powder, dessert-like snack, or via a feeding tube, with similar efficacy. EN may be recommended as a maintenance diet during the remission phases of Crohn’s Disease, combined with the usual diet. A maintenance enteral diet has been shown to increase the positive effects of biological therapies, thus preventing the relapse of the disease after surgical-induced remission. EN can also be administered as the only nutrition treatment, i.e., exclusive EN. Exclusive EN excludes solid food, providing the full amount of necessary calories. The use of this type of diet is particularly recommended during relapse of the disease, when it is applied for six to eight weeks to induce remission. Exclusive EN can be the main therapy for mild-to-moderate Crohn’s Disease in children and adolescents, as this regimen promotes, beside the remission of the illness in 80% to 85% of the cases, a reduced use of steroids, which are known to impair growth. Besides the primary function, exclusive EN provides other beneficial effects, such as improving the nutritional status and bone metabolism/turnover in children. Particularly for pediatric patients, over-the-counter formulas (recommended, and prescribed by their provider) could delay a child’s need to begin a more aggressive and more expensive biologic drug and allow them to stay in remission. Avoiding more expensive biologics and using medical nutrition instead, as provided in this bill, will reduce overall cost to the health care system. Finally, enteral formulas are currently covered by Medi-Cal Rx, and as currently drafted; this bill has zero impact on cost of Medi-Cal. While some commercial health plans also cover medical nutrition, such as enteral formulas, a gap remains. This bill simply aligns commercial health care coverage with what is already covered by Medi-Cal.
- Opposition. The California Association of Health Plans, Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write to oppose this bill because it is one of 14 health insurance mandate bills that will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. Benefit mandates impose a one-size-fits-all approach to medical care and benefit design driven by the legislature rather than consumer choice. These bills will lead to higher premiums, harming affordability and access for small businesses and individual market consumers. These opponents urge legislators to also consider the cumulative impacts of these mandates on premiums and access to coverage. All of these bills will increase costs and limit employer flexibility. The Legislature created the Office of Health Care Affordability to contain cost drivers. With this office in place and the state budget deficit, the Legislature should take a wait-and-see approach when considering costly mandates. The health plans have continued to be engaged and look forward to the work ahead.
SUPPORT AND OPPOSITION:
Support: Crohn’s and Colitis Foundation (sponsor)
California Association of Medical Product Suppliers
California Association of Orthodontists
California Children’s Hospital Association
California Chronic Care Coalition
California Life Sciences
Children’s Specialty Care Coalition
Oppose: America’s Health Insurance Plans
Association of California Life and Health Insurance Companies
California Association of Health Plans
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 1926
Author:(Connolly)
As Amended Ver:March 19, 2024
Majority vote
SUMMARY
Requires health plan contracts or disability insurance policies to provide coverage for dietary enteral formulas, as defined, for the treatment of regional enteritis. Defines dietary enteral formula as an enteral formula or enteral formulas that may be taken orally at home that are prescribed by a physician or nurse practitioner, or ordered by a registered dietician upon referral by a health care provider authorized to prescribe dietary treatments, as medically necessary for the treatment of regional enteritis.
Major Provisions
COMMENTS
California law currently requires coverage for the testing and treatment of Phenylketonuria (PKU) only and this bill includes coverage for dietary enteral formulas for the treatment of regional enteritis. This bill, as introduced, included treatment for chronic digestive diseases and inherited metabolic disorders. Digestive disorders are acute or chronic conditions affecting the digestive system which encompasses the gastrointestinal (GI) tract, liver, pancreas, and gallbladder. These conditions affect the body's ability to absorb nutrients, which can result in mild to severe symptoms, disability, or death. Digestive disorders such as inflammatory bowel disease (IBD) typically develop, or are identified, in adolescence and early adulthood, though it is possible for infants and children to be diagnosed with digestive disorders. Current therapies for digestive disorders typically include use of medication, such as steroids, anti-inflammatories, immunosupressives, or biologics, along with dietary management. The primary concern with digestive disorders is that they may lead to malnutrition, which can occur by a variety of mechanisms: symptoms may result in reduced food intake, the body may not sufficiently absorb nutrients taken in orally, loss of nutrients after absorption (enteric nutrient loss), or increased nutritional requirements due to inflammation. This bill was recently amended to specify coverage of dietary enteral formulas for the treatment of enteritis chronic digestive diseases. These types of diseases are also known as Crohn's disease which is a chronic inflammation of the digestive tract that leads to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Crohn's disease is an IBD and is an example of regional enteritis.
Enteral nutrition (EN) refers to oral nutritional formulas or tube feeding that may supplement or replace dietary modifications in order to restore nutritional requirements. EN involves delivery methods in which absorption occurs through the intestines; parenteral nutrition is delivered via the bloodstream using an intravenous tube. According to the Crohn's & Colitis Foundation, sponsors of this bill, EN is an important part of managing Crohn's disease in particular, as it reduces the inflammatory process of the gut, leading to bowel rest and improving postoperative prognosis for those who require surgery. EN is a liquid dietary regimen, which is administered orally, as a drink, powder, dessert-like snack, or via a feeding tube, with similar efficacy. EN may be recommended as a maintenance diet during the remission phases of Crohn's disease combined with the usual diet. A maintenance enteral diet has been shown to increase the positive effects of biological therapies, thus preventing the relapse of the disease after surgical-induced remission. EN can also be administered as the only nutrition treatment, i.e., exclusive enteral nutrition (EEN). EEN excludes solid food, providing the full amount of necessary calories. The use of this type of diet is particularly recommended during relapse of the disease, when it is applied for six to eight weeks to induce remission. EEN can be the main therapy for mild-to-moderate Crohn's disease in children and adolescents, as this regimen promotes, beside the remission of the illness in 80 to 85% of the cases, a reduced use of steroids, which are known to impair growth. The sponsor writes that EEN provides other beneficial effects, such as improving the nutritional status and bone metabolism/turnover in children. For pediatric patients, over the counter formulas, recommended and prescribed by their provider, could delay a child's need to begin a more aggressive and more expensive biologic drug and allow them to stay in remission.
- California Health Benefits Review Program (CHBRP) analysis. CHBRP's analysis of AB 620 (Connolly) of 2023, which is similar to this bill, includes the following:
- Assumptions. CHBRP states that it appears that formula and special food products administered via tube feeding are already covered in existing law. It should be noted that AB 620 included coverage of special food, which is not specified in this bill. CHBRP also notes that it appears as if treatments specified in this bill is already covered under Medi-Cal. For this analysis, CHBRP considers the following to be the most common digestive diseases that may benefit from formula and special food products: IBD including Crohn's disease and ulcerative colitis, cystic fibrosis, eosinophilic enteritis, enteropathy, chronic pancreatitis, and intestinal malabsorption. While CHBRP's analysis of AB 620 included inherited metabolic disorders, CHBRP notes that these disorders are individually rare and estimated to be about 1/3,000 individuals overall. Many of these are diagnosed through newborn screening, which is performed in order to initiate life- and brain-saving treatment early, before irreversible damage or death has occurred. These are often grouped into categories including: disorders of amino acid and protein metabolism (e.g., PKU, for which coverage of formula and special food products is already mandated), disorders of carbohydrate metabolism, and disorders of fatty acid oxidation metabolism. CHBRP assumes that this bill is focused on chronic conditions that may benefit from formula and special food products and would exclude various acute digestive disorders. CHBRP notes that if any of the assumptions listed above are incorrect, in particular, if this bill were to require coverage of formulas for acute conditions such as reflux, the cost impacts presented in this analysis may be significantly understated.
- Impact on expenditures. This bill would increase total net annual expenditures by $24,187,000, or 0.02%, for enrollees with Department of Managed Health Care (DMHC)-regulated plans and California Department of Insurance (CDI)-regulated policies. This is primarily due to a $26,928,000 increase in total health insurance premiums paid by employers and enrollees for newly covered benefits, adjusted by a $2,741,000 decrease in enrollee expenses for covered and/or noncovered benefits. Changes in premiums as a result of this bill would vary by market segment, with increases ranging from 0.0227% to 0.0268%. At baseline, for enrollees with inherited metabolic disorders, the annual cost is $6,369 for covered formulas and special food products and $5,846 for noncovered formulas and special food products; for enrollees with digestive disorders, the annual cost is $5,758 for covered formulas and special food products and $2,619 for noncovered formulas and special food products. Postmandate, the 579 enrollees with coverage for formulas and special food products at baseline would experience no change in cost sharing. For the 1,507 enrollees using services at baseline for whom postmandate benefit coverage would be new, enrollees would experience an average decrease in out-of-pocket expenses for noncovered benefits of $2,628. Within the individual DMHC-regulated market, health plans offered by Covered California would experience a 0.0263% premium increase, or $0.1729 per member per month (PMPM). Covered California individual market plans regulated by CDI would experience a 0.0280% increase in premiums, or $0.1500 PMPM.
- Medi-Cal. Based on the Medi-Cal Rx provider manual, Medi-Cal beneficiaries who have other inherited metabolic disorders or digestive disorders and are enrolled in DMHC-regulated plans already have coverage for formulas and special foods through Medi-Cal Rx.
- CalPERS. For enrollees associated with CalPERS in DMHC regulated plans, there would be a 0.0227% premium increase, or $0.1579 PMPM.
- Essential Health Benefits (EHBs). According to CHBRP, this bill does not exceed the definition of EHBs in California because formula and special food products are considered durable medical equipment and would be encompassed with the "rehabilitative and habilitative services and devices."
- Utilization. CHBRP estimates 148 commercial and CalPERS enrollees will use formula or special foods for other inherited metabolic disorders that are covered by insurance and an additional four enrollees use them as a noncovered benefit at baseline. Postmandate, 163 enrollees will use formulas or special food products covered by insurance, including the four who used them at baseline and 11 additional enrollees who begin using them due to the coverage expansion. CHBRP estimates 431 commercial and CalPERS enrollees will use formula or special foods for other digestive disorders that are covered by insurance and an additional 1,503 enrollees use them as a noncovered benefit at baseline. Postmandate, 5,185 enrollees will use formulas or special food products covered by insurance, including the 1,503 who used them at baseline and 3,251 additional enrollees who begin using them due to the coverage expansion. At baseline, a total of 579 enrollees with these conditions who use formula and special food products have coverage. Postmandate, a total of 4,769 enrollees would have new benefit coverage for these products, including 1,507 enrollees using these products at baseline and an additional 3,262 enrollees who begin using these products due to the coverage expansion.
According to the Author
Early treatment options for metabolic and digestive diseases, like Crohn's, have proven to reduce harm and increase quality of life. There is no reason why Californians suffering from chronic illnesses cannot lead full and productive lives. The author concludes that this bill provides patients with a proven successful alternative to certain medications, which healthcare providers may recommend when complications such as weight loss, surgery, obstruction, or severe inflammation, prevent patients from getting the right nutrients.
Arguments in Support
The Crohn's & Colitis Foundation, sponsors of this bill, writes IBD, which includes Crohn's disease and Ulcerative Colitis, causes chronic inflammation in the GI tract, the area of the body where digestion and absorption of nutrients take place. Normally, the immune system helps to protect the body from harmful infections and irritants. In IBD, however, the immune system reacts inappropriately, causing inflammation, which leads to symptoms such as abdominal pain and cramping, diarrhea, bleeding, weight loss, and/or fatigue. If left untreated, or when a patient is nonresponsive to treatment, complications can occur, which include malabsorption of nutrients, growth delays, and low bone mass. Avoiding more expensive biologics and using medical nutrition instead, as provided in this bill, will reduce overall cost to the health care system. Finally, the sponsor concludes that enteral formulas and currently covered by Medi-Cal RX, and as currently drafted, this bill has zero impact on cost of Medi-Cal. While some commercial health plans also cover medical nutrition, such as enteral formulas, a gap remains. This bill simply aligns commercial health care coverage with what is already covered by Medi-Cal.
Arguments in Opposition
The California Association of Health Plans (CAHP), the Association of California Life and Health Insurance Companies (ACLHIC), and America's Health Insurance Plans (AHIP) oppose mandates for health plans and insurers to cover specific services, as well as bills that eliminate cost sharing and limit utilization management, which have similar cost impacts as coverage mandates. Moreover, they will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. These bills will lead to higher premiums, harming affordability and access for small businesses and individual market consumers. CAHP, ACLHIC, and AHIP write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state's share of those mandates.
FISCAL COMMENTS
According to the Assembly Appropriations Committee:
- The DMHC estimates the total cost of this bill to be approximately $35,000 in fiscal year (FY) 2023-24, $458,000 in FY 2024-25, and $535,000 in FY 2025-26 and annually thereafter (Managed Care Fund). The majority of costs would be incurred by the Help Center, which anticipates additional workload for independent medical review, review organization, and medical expert review contracts. DMHC would also need to develop methodology and conduct health plan reviews for compliance with the requirements of this bill.
- One-time costs to CDI of $3,000 in FY 2024-25 (Insurance Fund).
- Cost pressure of an unknown amount, possibly in the hundreds of thousands of dollars annually, to CalPERS (General Fund, other funds). CHBRP estimated AB 620 (Connolly), of the current legislative session – a broader, but similar, bill – would increase total premiums for CalPERS health plans and insurance policies by $1.4 million; roughly 60% of these premiums are for state enrollees, and an unknown percentage is paid for by the state. Costs associated with this bill would probably be substantially lower.
According to the Legislative Analyst's Office, the General Fund faces a structural deficit in the tens of billions of dollars over the next several fiscal years.
VOTES
ASM HEALTH: 15-0-1
YES: Bonta, Waldron, Aguiar-Curry, Arambula, Wendy Carrillo, Flora, Haney, Jones-Sawyer, Maienschein, Joe Patterson, Rodriguez, Sanchez, Santiago, Schiavo, Weber
ABS, ABST OR NV: McCarty
ASM APPROPRIATIONS: 14-1-0
YES: Wicks, Sanchez, Arambula, Bryan, Calderon, Wendy Carrillo, Mike Fong, Grayson, Haney, Hart, Jim Patterson, Pellerin, Ta, Villapudua
NO: Dixon
UPDATED
VERSION: March 19, 2024
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0003146
Date of Hearing: April 17, 2024
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
ABPCA Bill Id:AB 1926
Author:(Connolly) – As Amended Ver:March 19, 2024
Policy Committee: | Health | Vote: | 15 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill requires a health plan or insurance policy to cover dietary enteral formulas that are deemed medically necessary, as specified, for the treatment of regional enteritis. The bill exempts specialized health plans and insurance and Medi-Cal managed care plans.
FISCAL EFFECT:
- The Department of Managed Health Care (DMHC) estimates the total cost of this bill to be approximately $35,000 in fiscal year (FY) 2023-24, $458,000 in FY 2024-25, and $535,000 in FY 2025-26 and annually thereafter (Managed Care Fund). The majority of costs would be incurred by the Help Center, which anticipates additional workload for independent medical review, review organization, and medical expert review contracts. DMHC would also need to develop methodology and conduct health plan reviews for compliance with the requirements of this bill.
- One-time costs to the Department of Insurance of $3,000 in FY 2024-25 (Insurance Fund).
- Cost pressure of an unknown amount, possibly in the hundreds of thousands of dollars annually, to the California Public Employees Retirement System (CalPERS) (General Fund, other funds). The California Health Benefits Review Program (CHBRP) estimated AB 620 (Connolly), of the current legislative session – a broader, but similar, bill – would increase total premiums for CalPERS health plans and insurance policies by $1.4 million; roughly 60% of these premiums are for state enrollees, and an unknown percentage is paid for by the state. Costs associated with this bill would probably be substantially lower.
According to the Legislative Analyst’s Office, the General Fund faces a structural deficit in the tens of billions of dollars over the next several fiscal years.
COMMENTS:
- Purpose. According to the author:
Early treatment options for metabolic and digestive diseases, like Crohn’s, have proven to reduce harm and increase quality of life. There is no reason why Californians suffering from chronic illnesses cannot lead full and productive lives. AB 1926 provides patients with a proven successful alternative to certain medications, which healthcare providers may recommend when complications such as weight loss, surgery, obstruction, or severe inflammation, prevent patients from getting the right nutrients.
- Background.
Regional Enteritis. Digestive disorders, such as regional enteritis, are acute or chronic conditions affecting the digestive system and the body’s ability to absorb nutrients, and can result in mild to severe symptoms, disability, or death. Digestive disorders may cause reduced food intake, insufficient absorption of ingested nutrients, loss of nutrients after absorption (enteric nutrient loss), or increased nutritional requirements due to inflammation, any of which may result in malnutrition. Regional enteritis, also known as Crohn’s disease, is a chronic inflammation of the digestive tract that leads to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition.
Enteral Nutrition. This bill requires coverage of dietary enteral formulas, or enteral nutrition, which means oral nutritional formulas or tube feeding that may supplement or replace dietary modifications. According to the Crohn’s & Colitis Foundation, sponsors of this bill, enteral nutrition is an important part of managing Crohn’s disease in particular, as it reduces the inflammatory process of the gut, allowing the bowel to rest, and improving postoperative prognosis for those who require surgery.
- Related Legislation. AB 620 would have required coverage of testing and treatment for chronic digestive diseases and inherited metabolic disorders – broader than the mandate in this bill, which includes coverage only for enteral formulas for Crohn’s disease. Governor Newsom vetoed AB 620, stating, in part:
I am concerned this bill would exceed the state's set of essential health benefits, which are established by the state's benchmark plan under the provisions of the federal Affordable Care Act (ACA). As such, this bill's mandate would require the state to defray the costs of coverage in Covered California. This would not only increase ongoing state General Fund costs, but it would set a new precedent by adding requirements that exceed the benchmark plan. A pattern of new coverage mandate bills like this could open the state to millions to billions of dollars in new costs to cover services relating to other health conditions. This creates uncertainty for our healthcare system's affordability. For these reasons, I cannot sign this bill.
- CHBRP Analysis. In its analysis of AB 620, CHBRP stated formula and special food products administered via tube feeding appear to be covered by existing law. AB 620 also included coverage of special food, which is not specified in this bill. CHBRP and this bill’s sponsor note Medi-Cal covers enteral nutrition. According to CHBRP, AB 620 did not exceed the definition of essential health benefits.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 2, 2024
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
ABPCA Bill Id:AB 1926
Author:((Connolly) – As Amended Ver:March 19, 2024
SUBJECT: Health care coverage: regional enteritis.
SUMMARY: Requires health plan contracts or disability insurance policies to provide coverage for dietary enteral formulas, as defined, for the treatment of regional enteritis. Specifically, this bill:
- Requires every health plan contract or disability insurance policy, on and after July 1, 2025, except a specialized health plan contract or disability insurance, to provide coverage for dietary enteral formulas, as defined in 4) below, for the treatment of regional enteritis.
- Requires coverage for the treatment of the chronic digestive diseases described in 1) above to include dietary enteral formulas that are part of a diet prescribed by a licensed physician and managed by a health care professional in consultation with a physician who specializes in the treatment of chronic digestive diseases and inherited metabolic disorders and who participates in or is authorized by the health plan, provided that the dietary enteral formula is deemed medically necessary to avert the development of serious physical or mental disabilities or to promote normal development or function as a consequence of regional enteritis.
- Exempts provisions of this bill from applying to Medi-Cal managed care plans contracting with the Department of Health Care Services, as specified.
- Defines dietary enteral formula as an enteral formula or enteral formulas that may be taken orally at home that are prescribed by a physician or nurse practitioner, or ordered by a registered dietician upon referral by a health care provider authorized to prescribe dietary treatments, as medically necessary for the treatment of regional enteritis.
EXISTING LAW:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 and the California Department of Insurance (CDI) to regulate health insurers. [Health and Safety Code (HSC) § 1340, et seq., and (Insurance Code (INS) § 106, et seq.]
- Establishes as California's essential health benefits (EHBs) benchmark under the Patient Protection and Affordable Care Act (ACA), the Kaiser Small Group Health Maintenance Organization, existing California health insurance mandates, and the 10 ACA mandated benefits. [HSC § 1367.005 and INS § 10112.27]
- Defines “basic health care services” as all of the following:
- Physician services, including consultation and referral;
- Hospital inpatient services and ambulatory care services;
- Diagnostic laboratory and therapeutic radiologic services;
- Home health services;
- Preventive health services;
- Emergency health care services, including ambulance and ambulance transport services and out-of-area coverage. Basic health care services includes ambulance and ambulance transport services provided through the 911 emergency response system; and,
- Hospice care. [HSC § 1345]
- Requires every health plan contract or disability insurance, on or after January 1, 2000, to provide coverage and treatment of Phenylketonuria (PKU). Requires coverage for PKU treatment to include those formulas and special food products that are part of a diet prescribed by a licensed physician and managed by a health care professional in consultation with a physician who specializes in the treatment of metabolic disease who participates in or is authorized by the plan or insurer, provided that the diet is deemed medically necessary to avert the development of serious physical or mental disabilities or to promote normal development or function as a consequence of PKU. Specifies that coverage is not required except to the extent that the cost of the necessary formulas and special food products exceeds the cost of a normal diet. Defines the following:
- Formula to mean an enteral product or enteral products for use at home that are prescribed by a physician or nurse practitioner, or ordered by a registered dietician upon referral by a health care provider authorized to prescribe dietary treatments, as medically necessary for the treatment of PKU; and,
- Special food product to mean a food product that is both of the following:
- Prescribed by a physician or nurse practitioner for the treatment of PKU consistent with the recommendations and best practices of qualified health professionals with expertise germane to, and experience in the treatment and care of, PKU, and does not include a food that is naturally low in protein, but may include a food product that is specially formulated to have less than one gram of protein per serving; and,
- Used in place of normal food products, such as grocery store foods, used by the general population. [HSC § 1374.56 and INS § 10123.89]
FISCAL EFFECT: Unknown. This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, early treatment options for metabolic and digestive diseases, like Crohn’s, have proven to reduce harm and increase quality of life. There is no reason why Californians suffering from chronic illnesses cannot lead full and productive lives. The author concludes that this bill provides patients with a proven successful alternative to certain medications, which healthcare providers may recommend when complications such as weight loss, surgery, obstruction, or severe inflammation, prevent patients from getting the right nutrients.
- BACKGROUND. California law currently requires coverage for the testing and treatment of PKU only and this bill includes coverage for dietary enteral formulas for the treatment of regional enteritis. It should be noted that this bill, as introduced, included treatment for chronic digestive diseases and inherited metabolic disorders. Digestive disorders are acute or chronic conditions affecting the digestive system which encompasses the gastrointestinal (GI) tract, liver, pancreas, and gallbladder. These conditions affect the body’s ability to absorb nutrients, which can result in mild to severe symptoms, disability, or death. Digestive disorders such as inflammatory bowel disease (IBD) typically develop, or are identified, in adolescence and early adulthood, though it is possible for infants and children to be diagnosed with digestive disorders. Current therapies for digestive disorders typically include use of medication, such as steroids, anti-inflammatories, immunosupressives, or biologics, along with dietary management. The primary concern with digestive disorders is that they may lead to malnutrition, which can occur by a variety of mechanisms: symptoms may result in reduced food intake, the body may not sufficiently absorb nutrients taken in orally, loss of nutrients after absorption (enteric nutrient loss), or increased nutritional requirements due to inflammation. This bill was recently amended to specify coverage of dietary enteral formulas for the treatment of enteritis chronic digestive diseases. These types of diseases are also known as Crohn’s disease which is a chronic inflammation of the digestive tract that leads to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Crohn’s disease is an IBD and is an example of regional enteritis.
Enteral nutrition (EN) refers to oral nutritional formulas or tube feeding that may supplement or replace dietary modifications in order to restore nutritional requirements. EN involves delivery methods in which absorption occurs through the intestines; parenteral nutrition is delivered via the bloodstream using an intravenous tube. According to the Crohn’s & Colitis Foundation, sponsors of this bill, EN is an important part of managing Crohn’s disease in particular, as it reduces the inflammatory process of the gut, leading to bowel rest and improving postoperative prognosis for those who require surgery. Enteral nutrition is a liquid dietary regimen, which is administered orally, as a drink, powder, dessert-like snack, or via a feeding tube, with similar efficacy. EN may be recommended as a maintenance diet during the remission phases of Crohn’s disease combined with the usual diet. A maintenance enteral diet has been shown to increase the positive effects of biological therapies, thus preventing the relapse of the disease after surgical-induced remission. EN can also be administered as the only nutrition treatment, i.e., exclusive enteral nutrition (EEN). EEN excludes solid food, providing the full amount of necessary calories. The use of this type of diet is particularly recommended during relapse of the disease, when it is applied for six to eight weeks to induce remission. EEN can be the main therapy for mild-to-moderate Crohn’s Disease in children and adolescents, as this regimen promotes, beside the remission of the illness in 80 to 85% of the cases, a reduced use of steroids, which are known to impair growth. The sponsor writes that EEN provides other beneficial effects, such as improving the nutritional status and bone metabolism/turnover in children. For pediatric patients, over the counter formulas, recommended and prescribed by their provider, could delay a child’s need to begin a more aggressive and more expensive biologic drug and allow them to stay in remission.
- California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson), Chapter 795, Statutes of 2002, requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost sharing, premiums, and other health insurance topics. CHBRP’s analysis of AB 620 (Connolly) of 2023, which is similar to this bill, includes the following:
- Assumptions. CHBRP states that it appears that formula and special food products administered via tube feeding are already covered in existing law. It should be noted that AB 620 included coverage of special food, which is not specified in this bill. CHBRP also notes that it appears as if treatments specified in this bill is already covered under Medi-Cal. For this analysis, CHBRP considers the following to be the most common digestive diseases that may benefit from formula and special food products: IBD including Crohn’s disease and ulcerative colitis, cystic fibrosis, eosinophilic enteritis, enteropathy, chronic pancreatitis, and intestinal malabsorption. While CHBRP’s analysis of AB 620 included inherited metabolic disorders, CHBRP notes that these disorders are individually rare and estimated to be about 1/3,000 individuals overall. Many of these are diagnosed through newborn screening, which is performed in order to initiate life- and brain-saving treatment early, before irreversible damage or death has occurred. These are often grouped into categories including: disorders of amino acid and protein metabolism (e.g., PKU, for which coverage of formula and special food products is already mandated), disorders of carbohydrate metabolism, and disorders of fatty acid oxidation metabolism. CHBRP assumes that this bill is focused on chronic conditions that may benefit from formula and special food products and would exclude various acute digestive disorders. CHBRP notes that if any of the assumptions listed above are incorrect, in particular, if this bill were to require coverage of formulas for acute conditions such as reflux, the cost impacts presented in this analysis may be significantly understated.
- Impact on expenditures. This bill would increase total net annual expenditures by $24,187,000, or 0.02%, for enrollees with DMHC-regulated plans and CDI-regulated policies. This is primarily due to a $26,928,000 increase in total health insurance premiums paid by employers and enrollees for newly covered benefits, adjusted by a $2,741,000 decrease in enrollee expenses for covered and/or noncovered benefits. Changes in premiums as a result of this bill would vary by market segment, with increases ranging from 0.0227% to 0.0268%. At baseline, for enrollees with inherited metabolic disorders, the annual cost is $6,369 for covered formulas and special food products and $5,846 for noncovered formulas and special food products; for enrollees with digestive disorders, the annual cost is $5,758 for covered formulas and special food products and $2,619 for noncovered formulas and special food products. Postmandate, the 579 enrollees with coverage for formulas and special food products at baseline would experience no change in cost sharing. For the 1,507 enrollees using services at baseline for whom postmandate benefit coverage would be new, enrollees would experience an average decrease in out-of-pocket expenses for noncovered benefits of $2,628. Within the individual DMHC-regulated market, health plans offered by Covered California would experience a 0.0263% premium increase, or $0.1729 per member per month (PMPM). Covered California individual market plans regulated by CDI would experience a 0.0280% increase in premiums, or $0.1500 PMPM.
- Medi-Cal. Based on the Medi-Cal Rx provider manual, Medi-Cal beneficiaries who have other inherited metabolic disorders or digestive disorders and are enrolled in DMHC-regulated plans already have coverage for formulas and special foods through Medi-Cal Rx.
- CalPERS. For enrollees associated with CalPERS in DMHC regulated plans, there would be a 0.0227% premium increase, or $0.1579 PMPM.
- Number of Uninsured in California. Since the change in average premiums does not exceed 1% for any market segment, CHBRP estimates this bill would have no measurable impact on the number of uninsured persons.
- EHBs. According to CHBRP, this bill does not exceed the definition of EHBs in California because formula and special food products are considered durable medical equipment and would be encompassed with the “rehabilitative and habilitative services and devices.”
- Medical effectiveness. CHBRP found limited evidence from two reviews that nutritional treatment is effective on induction and maintenance of remission in Crohn’s disease and comparatively effective to standard treatment (i.e., drug therapy). CHBRP found insufficient evidence from one systematic review on the efficacy of nutritional treatment for ulcerative colitis. Though the studies in the systematic review provide some evidence regarding the efficacy of nutritional treatment for ulcerative colitis, they were not specific to nutritional treatment alone, but to patients on an enteral nutrition diet and steroid therapy. CHBRP found insufficient evidence on the efficacy of nutritional treatment for inherited metabolic disorders. No studies were found that examined the effectiveness of nutritional treatment for inherited metabolic disorders, and available evidence on treatment for these disorders are treatment guidelines based on expert opinion. Limiting factors that contribute to this evidence grade are the small number of individuals with these conditions, need for timely treatment, and ethical barriers to conducting other types of studies with this population.
- Utilization. CHBRP estimates 148 commercial and CalPERS enrollees will use formula or special foods for other inherited metabolic disorders that are covered by insurance and an additional four enrollees use them as a noncovered benefit at baseline. Postmandate, 163 enrollees will use formulas or special food products covered by insurance, including the four who used them at baseline and 11 additional enrollees who begin using them due to the coverage expansion. CHBRP estimates 431 commercial and CalPERS enrollees will use formula or special foods for other digestive disorders that are covered by insurance and an additional 1,503 enrollees use them as a noncovered benefit at baseline. Postmandate, 5,185 enrollees will use formulas or special food products covered by insurance, including the 1,503 who used them at baseline and 3,251 additional enrollees who begin using them due to the coverage expansion. At baseline, a total of 579 enrollees with these conditions who use formula and special food products have coverage. Postmandate, a total of 4,769 enrollees would have new benefit coverage for these products, including 1,507 enrollees using these products at baseline and an additional 3,262 enrollees who begin using these products due to the coverage expansion.
- Public health. Due to the limited number of enrollees impacted, CHBRP concludes that this bill would have no measurable short-term or long-term public health impact. Although nutritional treatment for inherited metabolic disorders is supported by clinical guidelines, the change in utilization is small, and such disorders are rare. Although utilization of nutritional treatment for digestive disorders would increase, there is limited evidence that this treatment is effective for inducing or maintaining remission compared to standard drug treatment for Crohn’s disease and insufficient evidence on the effect of nutritional treatment for ulcerative colitis. Due to no measurable public health impact, CHBRP concludes that this bill would also have no impact on disparities in health outcomes. This bill would also have no measurable long term impact on public health, premature death, or societal economic losses.
- Long-term impacts. CHBRP estimates utilization after the initial 12 months from the enactment of this bill would likely stay similar to utilization estimates during the first 12 months postmandate. Utilization changes may occur if new prescription medications or other advancements change the treatment options available for enrollees with digestive or other inherited metabolic disorders. Similarly, utilization may be greater than estimated if detection capabilities improve or overall prevalence increases such that more enrollees are diagnosed with digestive or other inherited metabolic disorders; however, CHBRP is unable to predict these types of changes. In addition, health care utilization may change if effective management of a condition through increased use of newly covered formulas and special food products allows enrollees with digestive or other inherited metabolic disorders to delay use of other treatments such as prescription medications and surgery.
- OTHER STATES. The National Organization for Rare Disorders (NORD) publishes a state report card on coverage for medical nutrition, and for people with private insurance, the 2022 NORD report card shows that nine states mandate coverage for formula only, 27 states mandate coverage for medical nutrition more broadly, and 15 states do not mandate coverage. For people with state-funded insurance, 37 states mandate some degree of coverage for medical nutrition and 14 states do not mandate this coverage. New York law requires health insurers that cover prescription drugs to cover the cost of enteral formulas for home use, whether administered orally or via tube feeding, for which a physician or other licensed health care provider has issued a written order stating that the enteral formula is clearly medically necessary and has been proven effective as a disease-specific treatment regimen. The law lists specific diseases and disorders for which enteral formulas have been proven effective, including inherited diseases of amino acid or organic acid metabolism and Crohn's Disease.
- California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson), Chapter 795, Statutes of 2002, requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost sharing, premiums, and other health insurance topics. CHBRP’s analysis of AB 620 (Connolly) of 2023, which is similar to this bill, includes the following:
- SUPPORT. The Crohn’s & Colitis Foundation, sponsors of this bill, writes IBD, which includes Crohn’s disease and Ulcerative Colitis, causes chronic inflammation in the GI tract, the area of the body where digestion and absorption of nutrients take place. Normally, the immune system helps to protect the body from harmful infections and irritants. In IBD, however, the immune system reacts inappropriately, causing inflammation, which leads to symptoms such as abdominal pain and cramping, diarrhea, bleeding, weight loss, and/or fatigue. If left untreated, or when a patient is nonresponsive to treatment, complications can occur, which include malabsorption of nutrients, growth delays, and low bone mass. Some complications could lead to infection and then surgery, including removal of parts of the colon. Despite significant advances in medical care, complications are common, and ultimately occur in about 70% of Crohn’s disease patients. Avoiding more expensive biologics and using medical nutrition instead, as provided in this bill, will reduce overall cost to the health care system. Additionally, in its analysis of previous legislation, CHBRP, stated enteral formulas “do not exceed the definition of EHBs in California because formula and special food products are considered durable medical equipment and would be encompassed within the “rehabilitative and habilitative services and devices.” Finally, the sponsor concludes that enteral formulas and currently covered by Medi-Cal RX, and as currently drafted, this bill has zero impact on cost of Medi-Cal. While some commercial health plans also cover medical nutrition, such as enteral formulas, a gap remains. This bill simply aligns commercial health care coverage with what is already covered by Medi-Cal
- OPPOSITION. The California Association of Health Plans (CAHP), the Association of California Life and Health Insurance Companies (ACLHIC), and America’s Health Insurance Plans (AHIP) oppose mandates for health plans and insurers to cover specific services, as well as bills that eliminate cost sharing and limit utilization management, which have similar cost impacts as coverage mandates. Moreover, they will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. These bills will lead to higher premiums, harming affordability and access for small businesses and individual market consumers. CAHP, ACLHIC, and ACLHIC write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state’s share of those mandates.
- RELATED LEGISLATION.
- AB 3059 (Weber) requires health plan or insure coverage human milk and human milk derivatives covered under the Medi-Cal program as of 1988. AB 3059 is pending in Assembly Health Committee.
- SB 1290 (Roth) expresses the intent of the Legislature to review California’s EHBs benchmark plan and establish a new benchmark plan for the 2027 plan year. Limits the applicability of the current benchmark plan benefits to plan years on or before the 2027 plan year. SB 1290 is pending in Senate Health Committee.
- PREVIOUS LEGISLATION. AB 620 was substantially similar to this bill and vetoed by Governor Newsom:
“I am returning Assembly Bill 620 without my signature.
This bill would require health plans to cover formulas that are part of a medically necessary diet for the treatment of chronic digestive diseases and inherited metabolic disorders.
While I support individuals with these conditions having access to the nutritional support they may need, I am concerned this bill would exceed the state's set of essential health benefits, which are established by the state's benchmark plan under the provisions of the federal Affordable Care Act (ACA). As such, this bill's mandate would require the state to defray the costs of coverage in Covered California. This would not only increase ongoing state General Fund costs, but it would set a new precedent by adding requirements that exceed the benchmark plan. A pattern of new coverage mandate bills like this could open the state to millions to billions of dollars in new costs to cover services relating to other health conditions. This creates uncertainty for our healthcare system's affordability.
For these reasons, I cannot sign this bill.”
- COMMENTS.
- New mandate and impact to EHBs. CHBRP’s analysis notes that this bill does not exceed the definition of EHBs in California because formula is considered durable medical equipment and would be encompassed with the “rehabilitative and habilitative services and devices.” It is unclear whether the appropriate state regulators have conducted this analysis.
- Regional enteritis. The author may wish to define regional enteritis to clarify which conditions apply to this bill.
REGISTERED SUPPORT / OPPOSITION:
Support
Crohn’s & Colitis Foundation (sponsor)
California Association of Medical Product Suppliers
California Children's Hospital Assn.
Children's Specialty Care Coalition
Opposition
America’s Health Insurance Plans
Association of California Life and Health Insurance Companies
California Association of Health Plans
Analysis Prepared by: Kristene Mapile / HEALTH / (916) 319-2097
Discussed in Hearing
Senate Standing Committee on Health
Assembly Floor
Assembly Standing Committee on Health
Bill Author
Bill Co-Author(s):